Literature DB >> 19820673

Primary antiphospholipid syndrome: pregnancy outcome in a portuguese population.

Fatima Serrano1, Isabel Nogueira, Augusta Borges, Jorge Branco.   

Abstract

INTRODUCTION: Women with antiphospholipid syndrome (APS) may suffer from recurrent miscarriage, fetal death, fetal growth restriction (FGR), pre-eclampsia, placental abruption, premature delivery and thrombosis. Treatment with aspirin and low molecular weight heparin (LMWH) combined with close maternal-fetal surveillance can change these outcomes.
OBJECTIVE: To assess maternal and perinatal outcome in a cohort of Portuguese women with primary APS. PATIENTS AND METHODS: A retrospective analysis of 51 women with primary APS followed in our institution (January 1994 to December 2007). Forty one (80.4%) had past pregnancy morbidity and 35.3% (n=18) suffered previous thrombotic events. In their past they had a total of 116 pregnancies of which only 13.79 % resulted in live births. Forty four patients had positive anticardiolipin antibodies and 33 lupus anticoagulant. All women received treatment with low dose aspirin and LMWH.
RESULTS: There were a total of 67 gestations (66 single and one multiple). The live birth rate was 85.1% (57/67) with 10 pregnancy failures: seven in the first and second trimesters, one late fetal death and two medical terminations of pregnancy (one APS related). Mean (+/- SD) birth weight was 2837 +/- 812 g and mean gestational age 37 +/- 3.3 weeks. There were nine cases of FGR and 13 hypertensive complications (4 HELLP syndromes). 54.4% of the patients delivered by caesarean section.
CONCLUSIONS: In our cohort, early treatment with aspirin and LMWH combined with close maternal--fetal surveillance was associated with a very high chance of a live newborn.

Entities:  

Mesh:

Year:  2009        PMID: 19820673

Source DB:  PubMed          Journal:  Acta Reumatol Port        ISSN: 0303-464X            Impact factor:   1.290


  6 in total

Review 1.  Management of obstetric antiphospholipid syndrome.

Authors:  Guilherme Ribeiro Ramires de Jesus; Flavia Cunha dos Santos; Camila Souto Oliveira; Wallace Mendes-Silva; Nilson Ramires de Jesus; Roger Abramino Levy
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

Review 2.  Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment?

Authors:  Guilherme R de Jesús; Gustavo Rodrigues; Nilson R de Jesús; Roger A Levy
Journal:  Curr Rheumatol Rep       Date:  2014-02       Impact factor: 4.592

Review 3.  Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review.

Authors:  Amelia Ruffatti; Ariela Hoxha; Maria Favaro; Marta Tonello; Anna Colpo; Umberto Cucchini; Alessandra Banzato; Vittorio Pengo
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

4.  Pregnancy outcomes of antiphospholipid syndrome: In a low resource South Asian setting.

Authors:  C N Wijeyaratne; Sla Galappaththi; E Palipane; Dbia Jayawardane; S H Dodampahala; M N Tudawe; L V Gooneratne; R de Silva; D Ratnayake; S L Seneviratne
Journal:  Obstet Med       Date:  2016-03-17

Review 5.  Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults.

Authors:  Maria G Tektonidou; Laura Andreoli; Marteen Limper; Angela Tincani; Michael M Ward
Journal:  RMD Open       Date:  2019-04-28

6.  Effectiveness of high-dose i.v. immunoglobulin therapy for pregnant women with aspirin-heparin-resistant secondary antiphospholipid syndrome.

Authors:  Yoko Maesawa; Masashi Deguchi; Kenji Tanimura; Mayumi Morizane; Yasuhiko Ebina; Hideto Yamada
Journal:  Reprod Med Biol       Date:  2018-01-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.